Drug repurposing approach against Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase: insight from molecular dynamics simulations

References

• Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis infection. Mediterr J Hematol Infect Dis. 2013;5:e2013070.
   PubMedGoogle Scholar
• Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science. 1992;257:1055–1064.
   PubMed Web of Science ®Google Scholar
• Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev. 2008;21:305–333.
   PubMed Web of Science ®Google Scholar
• Floyd K, Glaziou P, Zumla A, et al. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the end TB era. Lancet Respir Med. 2018;6:299–314.
   PubMed Web of Science ®Google Scholar
• Chakaya J, et al. Global tuberculosis report 2020–reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021. doi:10.1016/j.ijid.2021.02.107.
   Google Scholar
• Sharma D, Sharma J, Deo N, et al. Prevalence and risk factors of tuberculosis in developing countries through health care workers. Microb Pathog. 2018;124:279–283.
   PubMed Web of Science ®Google Scholar
• Trinh QM, Nguyen HL, Do TN, et al. Tuberculosis and HIV co-infection in Vietnam. Int J Infect Dis. 2016;46:56–60.
   PubMed Web of Science ®Google Scholar
• da Silva Escada RO, Velasque L, Ribeiro SR, et al. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de janeiro, Brazil – associated factors and causes of death. BMC Infect Dis. 2017;17:1–10.
   PubMed Web of Science ®Google Scholar
• Oni T, et al. Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa-a cross sectional study. BMC Infect Dis. 2015;15:1–8.
   PubMed Web of Science ®Google Scholar
• Brust JCM, Shah NS, Mlisana K, et al. Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis–human immunodeficiency virus coinfection in South Africa. Clin Infect Dis. 2018;66:1246–1253.
   PubMed Web of Science ®Google Scholar
• Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685–1694.
   PubMed Web of Science ®Google Scholar
• Pedelacq J-D, Nguyen MC, Terwilliger TC, et al. A comprehensive review on Mycobacterium tuberculosis targets and drug development from a structural perspective. Struct Biol Drug Discov Methods Tech Pract. 2020:545–566. doi:10.1002/9781118681121.
   Google Scholar
• Santos LC. The molecular basis of resistance in Mycobaterium tuberculosis. Open J Med Microbiol. 2012;2:24–36.
   Google Scholar
• Shah NS, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(380):380–387.
   PubMedGoogle Scholar
• Shi R, Itagaki N, Sugawara I. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev Med Chem. 2007;7:1177–1185.
   PubMed Web of Science ®Google Scholar
• Saifullah A, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ. 2021;9(e10826). doi:10.7717/peerj.10826.
   PubMedGoogle Scholar
• Bonnet M, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS One. 2011;6(8):e23081. doi:10.1371/journal.pone.0023081.
   Google Scholar
• Organization, W. H. The global MDR-TB & XDR-TB response plan 2007–2008; 2007.
   Google Scholar
• Marrakchi H, Lanéelle G, Quémard A. Inha, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology. 2000;146:289–296.
   PubMed Web of Science ®Google Scholar
• Passi A, Rajput NK, Wild DJ, et al. RepTB: a gene ontology based drug repurposing approach for tuberculosis. J Cheminform. 2018;10:1–12.
   PubMed Web of Science ®Google Scholar
• Berman HM, et al. The protein data bank. Nucleic Acids Res. 2000;28:235–242.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Gordon JC, Myers JB, Folta T, et al. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368–W371.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
   PubMed Web of Science ®Google Scholar
• Hanwell MD, Curtis DE, Lonie DC, et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4:1–17.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–2791.
   PubMed Web of Science ®Google Scholar
• Guan B, Zhang C, Ning J. Genetic algorithm with a crossover elitist preservation mechanism for protein–ligand docking. Amb Express. 2017;7:1–11.
   PubMed Web of Science ®Google Scholar
• Perilla JR, Goh BC, Cassidy CK, et al. Molecular dynamics simulations of large macromolecular complexes. Curr Opin Struct Biol. 2015;31:64–74.
   PubMed Web of Science ®Google Scholar
• Tian C, Kasavajhala K, Belfon KAA, et al. ff19SB: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020;16:528–552.
   PubMed Web of Science ®Google Scholar
• Salomon-Ferrer R, Case DA, Walker RC. An overview of the Amber biomolecular simulation package. Wiley Interdiscip Rev Comput Mol Sci. 2013;3:198–210.
   Web of Science ®Google Scholar
• Salomon-Ferrer R, Götz AW, Poole D, et al. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. J Chem Theory Comput. 2013;9:3878–3888.
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel. 1995;8:127–134.
   Web of Science ®Google Scholar
• Gschwend DA, Good AC, Kuntz ID. Molecular docking towards drug discovery. J Mol Recognit An Interdiscip J. 1996;9:175–186.
   PubMed Web of Science ®Google Scholar
• Duff N, Peters B. Polymorph specific RMSD local order parameters for molecular crystals and nuclei: α-, β-, and γ-glycine. J Chem Phys. 2011;135(134101).
   PubMedGoogle Scholar
• Pontius J, Richelle J, Wodak SJ. Pontius, et al 1996 8950272.pdf; 1996. 121–136.
   Google Scholar
• Luckner SR, Liu N, Am Ende CW, et al. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem. 2010;285:14330–14337.
   PubMed Web of Science ®Google Scholar
• Kokkinidis M, Glykos NM, Fadouloglou VE. Protein flexibility and enzymatic catalysis. Adv Protein Chem Struct Biol. 2012;87:181–218.
   PubMed Web of Science ®Google Scholar
• Kuzmanic A, Zagrovic B. Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. Biophys J. 2010;98:861–871.
   PubMed Web of Science ®Google Scholar
• Benkovic SJ, Hammes-Schiffer S. A perspective on enzyme catalysis. Science. 2003;301:1196–1202.
   PubMed Web of Science ®Google Scholar
• Abseher R, Nilges M. Are there non-trivial dynamic cross-correlations in proteins? J Mol Biol. 1998;279:911–920.
   PubMed Web of Science ®Google Scholar
• Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10:307–317.
   PubMed Web of Science ®Google Scholar
• Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chemie Int Ed. 2003;42:1210–1250.
   PubMed Web of Science ®Google Scholar
• Micklefield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med Chem. 2001;8:1157–1179.
   PubMed Web of Science ®Google Scholar
• Perrin CL, Nielson JB. “Strong” hydrogen bonds in chemistry and biology. Annu Rev Phys Chem. 1997;48:511–544.
   PubMed Web of Science ®Google Scholar
• Patil R, et al. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One. 2010;5(e12029). doi:10.1371/journal.pone.0012029.
   Google Scholar
• David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins. In: Dennis R. Livesay, editor. Protein dynamics. Springer; 2014. p. 193–226.
   Google Scholar
• Granato D, Santos JS, Escher GB, et al. Use of principal component analysis (PCA) and hierarchical cluster analysis (HCA) for multivariate association between bioactive compounds and functional properties in foods: a critical perspective. Trends Food Sci Technol. 2018;72:83–90.
   Web of Science ®Google Scholar